Compare CELC & MWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | MWH |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.2B |
| IPO Year | 2017 | N/A |
| Metric | CELC | MWH |
|---|---|---|
| Price | $107.61 | $31.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $112.56 | $35.42 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 05-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.86 |
| Revenue Next Year | $720.19 | $14.78 |
| P/E Ratio | ★ N/A | $50.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $26.60 |
| 52 Week High | $151.02 | $48.40 |
| Indicator | CELC | MWH |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 41.87 |
| Support Level | $105.12 | $30.71 |
| Resistance Level | $117.61 | $37.44 |
| Average True Range (ATR) | 4.95 | 2.31 |
| MACD | 3.27 | -0.15 |
| Stochastic Oscillator | 90.28 | 20.08 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.